FDA - Spark Newswire

2 minute read

Hoth Therapeutics Announces Increased Results Of Its Alzheimer’s Therapeutic HT-ALZ; Shows Cognitive Improvements In Alzheimer’s Disease Mouse Model And Results Show Reduced Anxiety And Improved Performance

Today, 3:53 PM

HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc.

HOTH

1 minute read

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation

By Lara Goldstein

Today, 3:53 PM

Specialty ketamine company PharmaTher Holdings Ltd.

PHRRF

2 minute read

Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation Of Cell Proliferation Signals In Pre-Clinical Models; Shares Halted On Circuit Breaker To The Upside

By Happy Mohamed

Today, 3:53 PM

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE" --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN

LIXT

1 minute read

FDA
News

AC Immune Awarded New Grants From MJFF, Target ALS Supporting Programs Targeting TDP-43

By Benzinga Newsdesk

Today, 3:53 PM

The Michael J. Fox Foundation grant supports the development of AC Immune's first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration between AC Immune and world-class

ACIU

1 minute read

FDA
News

Teva Granted FDA Tentative Approval For Type 5 – New Formulation or New Manufacturer Of PACLITAXEL

By Charles Gross

Today, 3:53 PM

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216338

TEVA

3 minute read

T2 Biosystems Advances To The Phase 2 In HHS And The Steven And Alexandra Cohen Foundation’s LymeX Diagnostics Prize

By Happy Mohamed

Today, 3:53 PM

T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of

TTOO

1 minute read

Axcella Health Will Be Issued U.S. Patent Number 11,571,404 Tomorrow Titled “Compositions And Methods For The Treatment Of Liver Diseases And Disorders Associated With One Or Both Of Hyperammonemia Or Muscle Wasting”

By Happy Mohamed

Today, 3:53 PM

https://twitter.com/PatentGrants/status/1622660323923890177

AXLA

2 minute read

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’

By Vandana Singh

Today, 3:53 PM

The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…

BIIB

1 minute read

‘NuCana NUC-3373 In Combination With Other Agents In Patients With Advanced Solid Tumors’ – Clinical Trials

By Happy Mohamed

Today, 3:53 PM

https://clinicaltrials.gov/ct2/show/NCT05714553

NCNA

3 minute read

Centessa Pharmaceuticals To Present Additional Data From Open-Label Extension Of Phase 2a Study Of SerpinPC For Hemophilia At The 16th Annual Congress Of The European Association For Haemophilia And Allied Disorders On February 10, 2023

By Happy Mohamed

Today, 3:53 PM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present

CNTA